Three Month Road Map: California to Beef Up Impact of Billions for Stem Cell and Gene Therapy Research

Beginning steps for CIRM's new priorities

This is a brief listing of CIRM’s new priorities. During the next three months, CIRM will focus on starting to achieve goals one and four.

California’s $12 billion stem cell and gene therapy program is beginning the new year with aggressive plans to boost the impact of its research during what could be the last years of its life.

One of the top priorities for the next three months is aimed at propelling 15 to 20 therapies for prevalent diseases affecting Californians to late-stage clinical trials. This will mean consolidation and revisions in four old grant programs -- DISC2, TRAN1 through 4, and CLIN1. The new concept will be called Preclinical Development.

The push for 15-plus therapies will include